Impel NeuroPharma to Present at the 2021 Wedbush Pacgrow Virtual Healthcare Conference
August 03 2021 - 4:01PM
Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage
biopharmaceutical company focused on the development and
commercialization of transformative therapies for patients living
with central nervous system (CNS) diseases with high unmet medical
needs, today announced that Adrian Adams, chief executive officer,
will present on a panel titled “For Headaches THIS Big – The
Evolution of Migraine Therapeutic Landscape” at the 2021 Wedbush
Pacgrow Virtual Healthcare Conference on Tuesday, August 10, 2021
at 8:00-8:30 a.m. ET.
The conference will not be webcasting this panel discussion.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a late-stage
pharmaceutical company focused on utilizing its proprietary
technology to develop and commercialize transformative therapies
for people suffering from diseases with high unmet needs, with an
initial focus on diseases of the CNS. The Company’s strategy is to
rapidly advance its product candidate pipeline that pairs its
proprietary Precision Olfactory Delivery (POD®) system with
well-established therapeutics, including TRUDHESA™ for the acute
treatment of migraine, INP105 for the acute treatment of agitation
and aggression in patients with autism, and INP107 for OFF episodes
in Parkinson’s disease.
Investor Relations:Christina TartagliaStern
Investor RelationsPhone: (1)
212-362-1200Email: christina.tartaglia@sternir.com
Media Relations:Melyssa WeibleElixir Health
Public RelationsPhone: (1) 201-723-5805Email:
mweible@elixirhealthpr.com
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Sep 2023 to Sep 2024